Optimizing the long-term management of chronic migraine with onabotulinumtoxinA in real life

Cristina Tassorelli, Gioacchino Tedeschi, P. Sarchielli, Luigi Alberto Pini, Licia Grazzi, Pierangelo Geppetti, Marina De Tommaso, Marco Aguggia, P. Cortelli, Paolo Martelletti

Research output: Contribution to journalReview article

Abstract

Introduction: Management of chronic migraine is challenging. OnabotulinumtoxinA (OBT-A) is the only medication licensed for prevention of chronic migraine, and has been widely adopted in clinical practice. Limited data is available on its long-term use. Areas covered: Data from controlled trials are combined with available data on the long-term use of OBT-A in real-life studies, with information obtained in a recent survey among Italian headache centers, and the clinical experience of the authors. Six areas were identified as relevant to patients with chronic migraine: 1) definition of responders to OBT-A; 2) management of responders to OBT-A; 3) optimal timing of prophylaxis with OBT-A; 4) position of OBT-A in prevention of chronic migraine; 5) management of medication overuse, and 6) patient education. Expert commentary: This review provides an update on the latest evidence regarding the long-term use of OBT-A in chronic migraine and analyzes the critical issues in the decision-making process that emerge from the analysis of the literature and routine practice. A treatment algorithm is proposed for the adoption in the daily practice.

Original languageEnglish
Pages (from-to)167-176
Number of pages10
JournalExpert Review of Neurotherapeutics
Volume18
Issue number2
DOIs
Publication statusPublished - Feb 1 2018

Fingerprint

Migraine Disorders
Patient Education
Headache
Decision Making
onabotulinumtoxinA
Therapeutics

Keywords

  • Botox
  • chronic migraine
  • headache
  • migraine prophylaxis
  • onabotulinumtoxinA

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Pharmacology (medical)

Cite this

Optimizing the long-term management of chronic migraine with onabotulinumtoxinA in real life. / Tassorelli, Cristina; Tedeschi, Gioacchino; Sarchielli, P.; Pini, Luigi Alberto; Grazzi, Licia; Geppetti, Pierangelo; De Tommaso, Marina; Aguggia, Marco; Cortelli, P.; Martelletti, Paolo.

In: Expert Review of Neurotherapeutics, Vol. 18, No. 2, 01.02.2018, p. 167-176.

Research output: Contribution to journalReview article

Tassorelli, Cristina ; Tedeschi, Gioacchino ; Sarchielli, P. ; Pini, Luigi Alberto ; Grazzi, Licia ; Geppetti, Pierangelo ; De Tommaso, Marina ; Aguggia, Marco ; Cortelli, P. ; Martelletti, Paolo. / Optimizing the long-term management of chronic migraine with onabotulinumtoxinA in real life. In: Expert Review of Neurotherapeutics. 2018 ; Vol. 18, No. 2. pp. 167-176.
@article{3688cee17a224e599f57b2eeb178779a,
title = "Optimizing the long-term management of chronic migraine with onabotulinumtoxinA in real life",
abstract = "Introduction: Management of chronic migraine is challenging. OnabotulinumtoxinA (OBT-A) is the only medication licensed for prevention of chronic migraine, and has been widely adopted in clinical practice. Limited data is available on its long-term use. Areas covered: Data from controlled trials are combined with available data on the long-term use of OBT-A in real-life studies, with information obtained in a recent survey among Italian headache centers, and the clinical experience of the authors. Six areas were identified as relevant to patients with chronic migraine: 1) definition of responders to OBT-A; 2) management of responders to OBT-A; 3) optimal timing of prophylaxis with OBT-A; 4) position of OBT-A in prevention of chronic migraine; 5) management of medication overuse, and 6) patient education. Expert commentary: This review provides an update on the latest evidence regarding the long-term use of OBT-A in chronic migraine and analyzes the critical issues in the decision-making process that emerge from the analysis of the literature and routine practice. A treatment algorithm is proposed for the adoption in the daily practice.",
keywords = "Botox, chronic migraine, headache, migraine prophylaxis, onabotulinumtoxinA",
author = "Cristina Tassorelli and Gioacchino Tedeschi and P. Sarchielli and Pini, {Luigi Alberto} and Licia Grazzi and Pierangelo Geppetti and {De Tommaso}, Marina and Marco Aguggia and P. Cortelli and Paolo Martelletti",
year = "2018",
month = "2",
day = "1",
doi = "10.1080/14737175.2018.1419867",
language = "English",
volume = "18",
pages = "167--176",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Expert Reviews Ltd.",
number = "2",

}

TY - JOUR

T1 - Optimizing the long-term management of chronic migraine with onabotulinumtoxinA in real life

AU - Tassorelli, Cristina

AU - Tedeschi, Gioacchino

AU - Sarchielli, P.

AU - Pini, Luigi Alberto

AU - Grazzi, Licia

AU - Geppetti, Pierangelo

AU - De Tommaso, Marina

AU - Aguggia, Marco

AU - Cortelli, P.

AU - Martelletti, Paolo

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Introduction: Management of chronic migraine is challenging. OnabotulinumtoxinA (OBT-A) is the only medication licensed for prevention of chronic migraine, and has been widely adopted in clinical practice. Limited data is available on its long-term use. Areas covered: Data from controlled trials are combined with available data on the long-term use of OBT-A in real-life studies, with information obtained in a recent survey among Italian headache centers, and the clinical experience of the authors. Six areas were identified as relevant to patients with chronic migraine: 1) definition of responders to OBT-A; 2) management of responders to OBT-A; 3) optimal timing of prophylaxis with OBT-A; 4) position of OBT-A in prevention of chronic migraine; 5) management of medication overuse, and 6) patient education. Expert commentary: This review provides an update on the latest evidence regarding the long-term use of OBT-A in chronic migraine and analyzes the critical issues in the decision-making process that emerge from the analysis of the literature and routine practice. A treatment algorithm is proposed for the adoption in the daily practice.

AB - Introduction: Management of chronic migraine is challenging. OnabotulinumtoxinA (OBT-A) is the only medication licensed for prevention of chronic migraine, and has been widely adopted in clinical practice. Limited data is available on its long-term use. Areas covered: Data from controlled trials are combined with available data on the long-term use of OBT-A in real-life studies, with information obtained in a recent survey among Italian headache centers, and the clinical experience of the authors. Six areas were identified as relevant to patients with chronic migraine: 1) definition of responders to OBT-A; 2) management of responders to OBT-A; 3) optimal timing of prophylaxis with OBT-A; 4) position of OBT-A in prevention of chronic migraine; 5) management of medication overuse, and 6) patient education. Expert commentary: This review provides an update on the latest evidence regarding the long-term use of OBT-A in chronic migraine and analyzes the critical issues in the decision-making process that emerge from the analysis of the literature and routine practice. A treatment algorithm is proposed for the adoption in the daily practice.

KW - Botox

KW - chronic migraine

KW - headache

KW - migraine prophylaxis

KW - onabotulinumtoxinA

UR - http://www.scopus.com/inward/record.url?scp=85041346759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041346759&partnerID=8YFLogxK

U2 - 10.1080/14737175.2018.1419867

DO - 10.1080/14737175.2018.1419867

M3 - Review article

AN - SCOPUS:85041346759

VL - 18

SP - 167

EP - 176

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 2

ER -